Table 7. Risk of NPAEs associated with the use of pranlukast in the previous 7 days, stratified analysis according to age group, gender and season.
| Variables | Exposed in hazard period | Exposed in control period | Crude | Adjusted | P value for interaction* | ||||
| N/N | (%) | N/N | (%) | OR (95% CI)† | OR (95% CI)‡ | ||||
| Total | 3 568/64 800 | (5.51) | 13 633/259 200 | (0.05) | 1.07 | (1.02 to 1.12) | 1.26 | (1.21 to 1.32) | |
| Age group (years) | 0.5798 | ||||||||
| 0–2 | 422/3285 | (12.85) | 1655/13 140 | (12.60) | 1.03 | (0.90 to 1.17) | 1.18 | (1.03 to 1.34) | |
| 3–5 | 940/12 976 | (7.24) | 3644/51 904 | (7.02) | 1.05 | (0.96 to 1.14) | 1.21 | (1.11 to 1.33) | |
| 6–9 | 1076/22 671 | (4.75) | 4253/90 684 | (4.69) | 1.02 | (0.94 to 1.10) | 1.17 | (1.08 to 1.28) | |
| 10–12 | 226/5948 | (3.80) | 889/23 792 | (3.74) | 1.02 | (0.86 to 1.22) | 1.25 | (1.05 to 1.50) | |
| 13–19 | 904/19 920 | (4.54) | 3192/79 680 | (4.01) | 1.19 | (1.09 to 1.30) | 1.44 | (1.32 to 1.58) | |
| Gender | 0.9691 | ||||||||
| Male | 2294/39 257 | (5.84) | 8782/157 028 | (5.59) | 1.07 | (1.01 to 1.13) | 1.25 | (1.18 to 1.32) | |
| Female | 1274/25 543 | (4.99) | 4851/102 172 | (4.75) | 1.07 | (1.00 to 1.15) | 1.28 | (1.19 to 1.38) | |
| Season | <0.0001 | ||||||||
| Spring | 903/14 256 | (6.33) | 3038/57 024 | (5.33) | 1.29 | (1.18 to 1.42) | 1.47 | (1.34 to 1.61) | |
| Summer | 733/17 573 | (4.17) | 3233/70 292 | (4.60) | 0.87 | (0.79 to 0.96) | 1.08 | (0.98 to 1.19) | |
| Autumn | 1206/19 111 | (6.31) | 3996/76 444 | (5.23) | 1.31 | (1.21 to 1.42) | 1.53 | (1.41 to 1.65) | |
| Winter | 726/13 860 | (5.24) | 3366/55 440 | (6.07) | 0.81 | (0.74 to 0.89) | 0.96 | (0.88 to 1.06) | |
*
Joint test for exposure and strata variable interaction, indicating whether montelukast affects NPAEDs differently depending on age group, gender, and season.
†
Calculated by conditional logistic regression.
‡
Calculated by conditional logistic regression adjusted for concomitant medications.
NPAEsneuropsychiatric adverse events